Comparative Pharmacology
Head-to-head clinical analysis: ARICEPT versus REGONOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARICEPT versus REGONOL.
ARICEPT vs REGONOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible inhibitor of acetylcholinesterase, increasing acetylcholine levels in the synaptic cleft of the central nervous system.
Regorafenib is a multikinase inhibitor that targets various receptor tyrosine kinases involved in angiogenesis, oncogenesis, and tumor microenvironment, including VEGFR1-3, TIE2, PDGFR-β, FGFR1, KIT, RET, RAF-1, and BRAF.
Initial: 5 mg orally once daily for 4-6 weeks; may increase to 10 mg once daily. Maximum: 10 mg per day. Route: oral. Frequency: once daily.
Intravenous: 400 mg every 12 hours for 60 doses. Maintenance: 400 mg twice daily for 180 days (6 months).
None Documented
None Documented
70 hours (terminal elimination half-life; steady-state reached in 15-21 days; once-daily dosing appropriate)
Terminal half-life of 2–4 hours; clinically relevant for dosing every 6–8 hours in renal impairment.
Renal (57% unchanged drug, 17% as metabolites), fecal (30%), biliary (minimal)
Approximately 70% renal (unchanged) and 30% biliary/fecal as glucuronide conjugates.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor